Literature DB >> 23247046

HDAC inhibition by SNDX-275 (Entinostat) restores expression of silenced leukemia-associated transcription factors Nur77 and Nor1 and of key pro-apoptotic proteins in AML.

L Zhou1, V R Ruvolo, T McQueen, W Chen, I J Samudio, O Conneely, M Konopleva, M Andreeff.   

Abstract

Nur77 and Nor1 are highly conserved orphan nuclear receptors. We have recently reported that nur77(-/-)nor1(-/-) mice rapidly develop acute myeloid leukemia (AML) and that Nur77 and Nor1 transcripts were universally downregulated in human AML blasts. These findings indicate that Nur77 and Nor1 function as leukemia suppressors. We further demonstrated silencing of Nur77 and Nor1 in leukemia stem cells (LSCs). We here report that inhibition of histone deacetylase (HDAC) using the specific class I HDAC inhibitor SNDX-275 restored the expression of Nur77/Nor1 and induced expression of activator protein 1 transcription factors c-Jun and JunB, and of death receptor TRAIL, in AML cells and in CD34(+)/38(-) AML LSCs. Importantly, SNDX-275 induced extensive apoptosis in AML cells, which could be suppressed by silencing nur77 and nor1. In addition, pro-apoptotic proteins Bim and Noxa were transcriptionally upregulated by SNDX-275 in AML cells and in LSCs. Our present work is the first report of a novel mechanism of HDAC inhibitor-induced apoptosis in AML that involves restoration of the silenced nuclear receptors Nur77 and Nor1, activation of activator protein 1 transcription factors, a death receptor and pro-apoptotic proteins.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23247046      PMCID: PMC3892989          DOI: 10.1038/leu.2012.366

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  50 in total

1.  Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia.

Authors:  Marina Konopleva; Rooha Contractor; Twee Tsao; Ismael Samudio; Peter P Ruvolo; Shinichi Kitada; Xingming Deng; Dayong Zhai; Yue-Xi Shi; Thomas Sneed; Monique Verhaegen; Maria Soengas; Vivian R Ruvolo; Teresa McQueen; Wendy D Schober; Julie C Watt; Tilahun Jiffar; Xiaoyang Ling; Frank C Marini; David Harris; Martin Dietrich; Zeev Estrov; James McCubrey; W Stratford May; John C Reed; Michael Andreeff
Journal:  Cancer Cell       Date:  2006-11       Impact factor: 31.743

2.  Phase 1/2 study of the combination of 5-aza-2'-deoxycytidine with valproic acid in patients with leukemia.

Authors:  Guillermo Garcia-Manero; Hagop M Kantarjian; Blanca Sanchez-Gonzalez; Hui Yang; Gary Rosner; Srdan Verstovsek; Michael Rytting; William G Wierda; Farhad Ravandi; Charles Koller; Lianchun Xiao; Stefan Faderl; Zeev Estrov; Jorge Cortes; Susan O'brien; Elihu Estey; Carlos Bueso-Ramos; Jackie Fiorentino; Elias Jabbour; Jean-Pierre Issa
Journal:  Blood       Date:  2006-08-01       Impact factor: 22.113

3.  Regulation of macrophage inflammatory gene expression by the orphan nuclear receptor Nur77.

Authors:  Liming Pei; Antonio Castrillo; Peter Tontonoz
Journal:  Mol Endocrinol       Date:  2005-12-08

Review 4.  MS-275, a potent orally available inhibitor of histone deacetylases--the development of an anticancer agent.

Authors:  Holger Hess-Stumpp; Tomke Ute Bracker; David Henderson; Oliver Politz
Journal:  Int J Biochem Cell Biol       Date:  2007-02-16       Impact factor: 5.085

Review 5.  Molecular targets and the treatment of myeloid leukemia.

Authors:  A Ikeda; D B Shankar; M Watanabe; F Tamanoi; T B Moore; K M Sakamoto
Journal:  Mol Genet Metab       Date:  2006-05-05       Impact factor: 4.797

6.  Induction of apoptosis in PA-1 ovarian cancer cells by vitamin K2 is associated with an increase in the level of TR3/Nur77 and its accumulation in mitochondria and nuclei.

Authors:  Toshiko Sibayama-Imazu; Yukari Fujisawa; Yutaka Masuda; Toshihiro Aiuchi; Shigeo Nakajo; Hiroyuki Itabe; Kazuyasu Nakaya
Journal:  J Cancer Res Clin Oncol       Date:  2008-01-17       Impact factor: 4.553

7.  Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes.

Authors:  Guillermo Garcia-Manero; Hui Yang; Carlos Bueso-Ramos; Alessandra Ferrajoli; Jorge Cortes; William G Wierda; Stefan Faderl; Charles Koller; Gail Morris; Gary Rosner; Andrey Loboda; Valeria R Fantin; Sophia S Randolph; James S Hardwick; John F Reilly; Cong Chen; Justin L Ricker; J Paul Secrist; Victoria M Richon; Stanley R Frankel; Hagop M Kantarjian
Journal:  Blood       Date:  2007-10-25       Impact factor: 22.113

8.  Abrogation of nuclear receptors Nr4a3 and Nr4a1 leads to development of acute myeloid leukemia.

Authors:  Shannon E Mullican; Shuo Zhang; Marina Konopleva; Vivian Ruvolo; Michael Andreeff; Jeffrey Milbrandt; Orla M Conneely
Journal:  Nat Med       Date:  2007-05-21       Impact factor: 53.440

9.  Apoptosis induced by histone deacetylase inhibitors in leukemic cells is mediated by Bim and Noxa.

Authors:  S Inoue; J Riley; T W Gant; M J S Dyer; G M Cohen
Journal:  Leukemia       Date:  2007-05-24       Impact factor: 11.528

10.  During negative selection, Nur77 family proteins translocate to mitochondria where they associate with Bcl-2 and expose its proapoptotic BH3 domain.

Authors:  Jennifer Thompson; Astar Winoto
Journal:  J Exp Med       Date:  2008-04-28       Impact factor: 14.307

View more
  23 in total

1.  Mcl-1 dependence predicts response to vorinostat and gemtuzumab ozogamicin in acute myeloid leukemia.

Authors:  William E Pierceall; Ryan J Lena; Bruno C Medeiros; Noel Blake; Camille Doykan; Michael Elashoff; Michael H Cardone; Roland B Walter
Journal:  Leuk Res       Date:  2014-02-28       Impact factor: 3.156

2.  HDAC1 Is a Required Cofactor of CBFβ-SMMHC and a Potential Therapeutic Target in Inversion 16 Acute Myeloid Leukemia.

Authors:  Lisa E Richter; Yiqian Wang; Michelle E Becker; Rachel A Coburn; Jacob T Williams; Catalina Amador; R Katherine Hyde
Journal:  Mol Cancer Res       Date:  2019-02-27       Impact factor: 5.852

3.  Epigenetic regulation of the NR4A orphan nuclear receptor NOR1 by histone acetylation.

Authors:  Yue Zhao; Takashi Nomiyama; Hannes M Findeisen; Hua Qing; Jun Aono; Karrie L Jones; Elizabeth B Heywood; Dennis Bruemmer
Journal:  FEBS Lett       Date:  2014-11-21       Impact factor: 4.124

4.  Strong Correlation between the Expression Levels of HDAC4 and SIRT6 in Hematological Malignancies of the Adults.

Authors:  Zsuzsanna Gaál; Éva Oláh; László Rejtő; Ferenc Erdődi; László Csernoch
Journal:  Pathol Oncol Res       Date:  2016-10-20       Impact factor: 3.201

5.  Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.

Authors:  Angie M Torres-Adorno; Jangsoon Lee; Takahiro Kogawa; Peter Ordentlich; Debu Tripathy; Bora Lim; Naoto T Ueno
Journal:  Clin Cancer Res       Date:  2017-05-02       Impact factor: 12.531

Review 6.  Vorinostat in autophagic cell death: A critical insight into autophagy-mediated, -associated and -dependent cell death for cancer prevention.

Authors:  Srimanta Patra; Prakash P Praharaj; Daniel J Klionsky; Sujit K Bhutia
Journal:  Drug Discov Today       Date:  2021-08-13       Impact factor: 7.851

7.  Possible role of intragenic DNA hypermethylation in gene silencing of the tumor suppressor gene NR4A3 in acute myeloid leukemia.

Authors:  Ryo Shimizu; Tomoya Muto; Kazumasa Aoyama; Kwangmin Choi; Masahiro Takeuchi; Shuhei Koide; Nagisa Hasegawa; Yusuke Isshiki; Emi Togasaki; Chika Kawajiri-Manako; Yuhei Nagao; Shokichi Tsukamoto; Shio Sakai; Yusuke Takeda; Naoya Mimura; Chikako Ohwada; Emiko Sakaida; Tohru Iseki; Daniel T Starczynowski; Atsushi Iwama; Koutaro Yokote; Chiaki Nakaseko
Journal:  Leuk Res       Date:  2016-09-26       Impact factor: 3.156

8.  Nuclear receptor 4A (NR4A) family - orphans no more.

Authors:  Stephen Safe; Un-Ho Jin; Benjamin Morpurgo; Ala Abudayyeh; Mandip Singh; Ronald B Tjalkens
Journal:  J Steroid Biochem Mol Biol       Date:  2015-04-23       Impact factor: 4.292

Review 9.  Minireview: role of orphan nuclear receptors in cancer and potential as drug targets.

Authors:  Stephen Safe; Un-Ho Jin; Erik Hedrick; Alexandra Reeder; Syng-Ook Lee
Journal:  Mol Endocrinol       Date:  2013-12-02

Review 10.  EZH2 in normal and malignant hematopoiesis.

Authors:  K Lund; P D Adams; M Copland
Journal:  Leukemia       Date:  2013-10-07       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.